ERBB2 and breast carcinoma: Results from the immunostaining analysis revealed that PD-L1 expression in TILs and cancer cells was higher in HER2-positive mammary carcinoma, as reported in humans [2,3,16,20,22], contrasting with TN mammary carcinoma tumor samples.